Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory - Episode 5

CAR T and Evolving Treatment Paradigms for Early R/R MM

Panelists discuss the evolution of chimeric antigen receptor (CAR) T-cell therapy for patients with relapsed/refractory multiple myeloma (R/R MM), the factors that inform its use, and how treatment approaches differ for standard-risk vs functional high-risk patients.

EP. 1: Emerging Updates in Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Discussion of the CEPHEUS Trial.
EP. 2: Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma
EP. 3: Academic Perspectives in Front-Line Treatment Goals in Newly Diagnosed Transplant-Ineligible Multiple Myeloma
EP. 4: Future Considerations for Front-line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
Now Viewing
EP. 5: CAR T and Evolving Treatment Paradigms for Early R/R MM

Video content above is prompted by the following:

  • How has the use of CAR T evolved for patients with R/R multiple myeloma and what factors inform your practice?
  • Where does CAR T fall in your treatment paradigm? How does your approach differ with patients who are standard risk vs functional high risk?